Trials / Terminated
TerminatedNCT04551885
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
A Phase I, Open-Label, Multicenter Study of FT516 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Fate Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FT516 | Experimental Interventional Therapy |
| DRUG | Avelumab | Monoclonal antibody |
| DRUG | Cyclophosphamide | Lympho-conditioning agent |
| DRUG | Fludarabine | Lympho-conditioning agent |
| DRUG | IL-2 | Biologic response modifier |
Timeline
- Start date
- 2020-09-07
- Primary completion
- 2023-08-11
- Completion
- 2023-08-11
- First posted
- 2020-09-16
- Last updated
- 2023-09-21
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04551885. Inclusion in this directory is not an endorsement.